Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå : ¶óµð¿À ¾ÆÀ̼ÒÅäÇÁº°, ¿ëµµº°, À̹Ì¡ ¸ð´Þ¸®Æ¼º°, Áúȯ ÀûÀÀÁõº°, ÃÖÁ¾ »ç¿ëÀÚº°, Áö¿ªº°
Diagnostic Radioisotopes Market, By Radioisotope, By Application, By Imaging Modality, By Disease Indication, By End User, By Geography
»óǰÄÚµå : 1392012
¸®¼­Ä¡»ç : Coherent Market Insights
¹ßÇàÀÏ : 2023³â 11¿ù
ÆäÀÌÁö Á¤º¸ : ¿µ¹®
 ¶óÀ̼±½º & °¡°Ý (ºÎ°¡¼¼ º°µµ)
US $ 4,500 £Ü 6,385,000
PDF (Single User License) help
PDF º¸°í¼­¸¦ 1¸í¸¸ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 7,000 £Ü 9,933,000
PDF (Multi User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ »ç¾÷Àå¿¡¼­ 7¸í±îÁö ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.
US $ 10,000 £Ü 14,191,000
PDF (Enterprise User License) help
PDF º¸°í¼­¸¦ µ¿ÀÏ ±â¾÷ÀÇ ¸ðµç ºÐÀÌ ÀÌ¿ëÇÒ ¼ö ÀÖ´Â ¶óÀ̼±½ºÀÔ´Ï´Ù. Àμ⠰¡´ÉÇϸç Àμ⹰ÀÇ ÀÌ¿ë ¹üÀ§´Â PDF ÀÌ¿ë ¹üÀ§¿Í µ¿ÀÏÇÕ´Ï´Ù.


¤± Add-on °¡´É: °í°´ÀÇ ¿äû¿¡ µû¶ó ÀÏÁ¤ÇÑ ¹üÀ§ ³»¿¡¼­ CustomizationÀÌ °¡´ÉÇÕ´Ï´Ù. ÀÚ¼¼ÇÑ »çÇ×Àº ¹®ÀÇÇØ Áֽñ⠹ٶø´Ï´Ù.

Çѱ۸ñÂ÷

¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå ±Ô¸ð´Â 2023³â 56¾ï 7,000¸¸ ´Þ·¯·Î Æò°¡µÇ¾ú°í 2030³â¿¡´Â 103¾ï 6,000¸¸ ´Þ·¯¿¡ À̸¦ °ÍÀ¸·Î ¿¹ÃøµÇ¸ç, ¿¹Ãø ±â°£ Áß º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9%¸¦ ³ªÅ¸³¾ Àü¸ÁÀÔ´Ï´Ù.

º¸°í ´ë»ó ¹üÀ§ º¸°í¼­ ¼¼ºÎÁ¤º¸
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 56¾ï 7,000¸¸ ´Þ·¯
¾÷Àû µ¥ÀÌÅÍ 2018³â-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ÀÇ º¹ÇÕ ¿¬°£ ¼ºÀå·ü(CAGR) 9.00% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 103¾ï 6,000¸¸ ´Þ·¯
±×¸² 1. ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå Á¡À¯À²(%), Áö¿ªº°, 2023³â
Diagnostic Radioisotopes Market-IMG1

¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀåÀº ¸¸¼º Áúȯ Áõ°¡, ÀÇ·á ¿µ»ó ±â¼úÀÇ Áøº¸, Á¤È®ÇÑ Áø´Ü ÀýÂ÷¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó ÇöÀúÇÑ ¼ºÀåÀ» ÀÌ·ç°í ÀÖ½À´Ï´Ù. Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò´Â ´Ù¾çÇÑ Áúº´°ú »óŸ¦ Áø´ÜÇϱâ À§ÇØ ÀÇ·á ¿µ»ó Áø´Ü¿¡ »ç¿ëµÇ´Â ¹æ»ç¼º ¹°ÁúÀÔ´Ï´Ù. ÀÌ·¯ÇÑ ¹æ»ç¼º µ¿À§¿ø¼Ò´Â ¹æ»ç¼±À» ¹æÃâÇÏ°í ¿µ»ó Áø´ÜÀåÄ¡·Î °ËÃâÇÒ ¼ö Àֱ⠶§¹®¿¡ ÇコÄɾî Àü¹®°¡´Â ½ÅüÀÇ ³»ºÎ±¸Á¶¸¦ °¡½ÃÈ­ÇÏ°í ºÐ¼®ÇÒ ¼ö ÀÖ½À´Ï´Ù.

½ÃÀå ¿ªÇÐ:

¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀåÀº ¿©·¯ ¿äÀÎÀÇ ¿µÇâÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ¾Ï, ½ÉÇ÷°ü Áúȯ, ½Å°æ Áúȯ µîÀÇ ¸¸¼º Áúȯ Áõ°¡·Î Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ¼ö¿ä°¡ ³ô¾ÆÁö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ ¹æ»ç¼ºµ¿À§¿ø¼Ò´Â ¾çÀüÀÚ ¹æ»ç ´ÜÃþ ÃÔ¿µ¹ý(PET), ´Ü±¤ÀÚ¹æ»çÄÄÇ»ÅÍ ´ÜÃþÃÔ¿µ¹ý(SPECT), °¨¸¶ Ä«¸Þ¶ó µî ´Ù¾çÇÑ ¿µ»ó Áø´Ü ±â¼ú¿¡ »ç¿ëµÇ¾î ÀÌ·¯ÇÑ ÁúȯÀ» °ËÃâ ¹× Áø´ÜÇÕ´Ï´Ù.

±×·¯³ª ½ÃÀå ¼ºÀåÀ» ¹æÇØÇÏ´Â ¿äÀεµ ÀÖ½À´Ï´Ù. Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼ÒÀÇ ºñ¿ëÀÌ ³ô°í, Á¦Á¶ ¹× »ç¿ë¿¡ °üÇÑ ±ÔÁ¦ ¿ä°ÇÀÌ ¾ö°ÝÇÑ °ÍÀÌ ½ÃÀå ¼ºÀåÀÇ °úÁ¦°¡ µÇ°í ÀÖ½À´Ï´Ù. ¹æ»ç¼º µ¿À§¿ø¼ÒÀÇ À̿밡´É¼ºÀÌ Á¦ÇÑÀûÀ̰ųª ÀϺΠµ¿À§¿ø¼ÒÀÇ ¹Ý°¨±â°¡ ª±â ¶§¹®¿¡ ƯÁ¤ Áø´Ü ÀýÂ÷¿¡¼­ÀÇ »ç¿ëÀÌ Á¦ÇÑµÉ ¼ö ÀÖ½À´Ï´Ù.

ÀÌ·¯ÇÑ °úÁ¦¿¡µµ ºÒ±¸ÇÏ°í ½ÃÀå¿¡´Â ¸î °¡Áö ¼ºÀå ±âȸ°¡ ÀÖ½À´Ï´Ù. PET/CT³ª SPECT/CT µîÀÇ ÇÏÀ̺긮µå À̹Ì¡ ±â¼úÀÇ Ã¤¿ëÀÌ Áõ°¡Çϰí ÀÖ¾î Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ¼ö¿ä¸¦ ²ø¾î¿Ã¸± °ÍÀ¸·Î ¿¹»óµË´Ï´Ù. ¶ÇÇÑ »õ·Î¿î ¹æ»ç¼º µ¿À§ ¿ø¼Ò¿Í ¹æ»ç¼º ÀǾàǰ ½ÃÀå °³Ã´, À̹Ì¡ ±â¼úÀÇ Áøº¸·Î ½ÃÀå¿¡ »õ·Î¿î ±âȸ°¡ »ý±æ °ÍÀ¸·Î ±â´ëµÇ°í ÀÖ½À´Ï´Ù.

¿¹¸¦ µé¾î, 2023³â 3¿ù 16ÀÏ Á¦¾à»ç Telix Pharmaceuticals Limited.´Â ¹Ì±¹ ½ÄǰÀǾ౹(FDA)ÀÌ Illuccix(°¥·ý Ga 68 °íÁ¦Å䯼µå ÁÖ»çÁ¦ Á¦Á¶¿ë ŰƮ)¸¦ Ãß°¡ ½Å¾à ½ÂÀÎ ½Åû(sNDA)À» ½Ç½ÃÇÏ¿© 177Lu 177PSMA ÁöÇ⼺ Ä¡·á°¡ ÀûÀÀÀÌ µÇ´Â ÀüÀ̼º Àü¸³¼±¾Ï ȯÀÚÀÇ ¼±Åÿ¡ »ç¿ëÇÒ ¼ö ÀÖ°Ô µÇ¾ú½À´Ï´Ù°í ¹ßÇ¥Çß½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

Á¦2Àå ½ÃÀå Àü¸Á

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

Á¦4Àå ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå - Äڷγª¹ÙÀÌ·¯½º(COVID-19) ÆÒµ¥¹ÍÀÇ ¿µÇâ

Á¦5Àå ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå : ¶óµð¿À ¾ÆÀ̼ÒÅäÇÁº°(2023³â-2030³â)

Á¦6Àå ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå : ¿ëµµº°(2023³â-2030³â)

Á¦7Àå ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå : À̹Ì¡ ¸ð´Þ¸®Æ¼º°(2023³â-2030³â)

Á¦8Àå ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå : ÀûÀÀÁõº°(2023³â-2030³â)

Á¦9Àå ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2023³â-2030³â)

Á¦10Àå ¼¼°è Áø´Ü¿ë ¹æ»ç¼± µ¿À§ ¿ø¼Ò ½ÃÀå : Áö¿ªº°(2023³â-2030³â)

Á¦11Àå °æÀï ±¸µµ

Á¦12Àå ¼½¼Ç

BJH
¿µ¹® ¸ñÂ÷

¿µ¹®¸ñÂ÷

Global diagnostic radioisotopes market size is expected to reach US$ 10.36 Bn by 2030, from US$ 5.67 Bn in 2023, at a CAGR of 9% during the forecast period

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 5.67 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 9.00% 2030 Value Projection: US$ 10.36 Bn
Figure 1. Global Diagnostic Radioisotopes Market Share (%), By Region, 2023
Diagnostic Radioisotopes Market - IMG1

Global diagnostic radioisotopes market is witnessing significant growth due to increasing prevalence of chronic diseases, advancements in medical imaging technology, and rising demand for accurate diagnostic procedures. Diagnostic radioisotopes are radioactive substances that are used in medical imaging to diagnose various diseases and conditions. These isotopes emit radiation that can be detected by imaging devices, allowing healthcare professionals to visualize and analyze the internal structures of the body.

Market Dynamics:

Global diagnostic radioisotopes market are influenced by several factors. Increasing prevalence of chronic diseases such as cancer, cardiovascular diseases, and neurological disorders boosts demand for diagnostic radioisotopes. These isotopes are used in various imaging techniques such as positron emission tomography (PET), single-photon emission computed tomography (SPECT), and gamma cameras to detect and diagnose these diseases.

However, there are certain restraints that may hinder the growth of the market. The high cost of diagnostic radioisotopes and the stringent regulatory requirements for their production and use pose challenges for market growth. The limited availability of radioisotopes and the short half-life of some isotopes may limit their use in certain diagnostic procedures.

Despite these challenges, the market presents several opportunities for growth. Increasing adoption of hybrid imaging techniques, such as PET/CT and SPECT/CT, is expected to boost demand for diagnostic radioisotopes. Moreover, the development of novel radioisotopes and radiopharmaceuticals, as well as advancements in imaging technology, are expected to create new opportunities in the market.

For instance, on March 16, 2023, Telix Pharmaceuticals Limited., a pharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) had approved a supplementary New Drug Application (sNDA) for Illuccix (kit for the preparation of gallium Ga 68 gozetotide injection) to enable its use for the selection of patients with metastatic prostate cancer, for whom 177Lu 177 PSMA-directed therapy is indicated.

Key features of the study:

Detailed Segmentation:

Table of Contents

1. Research Objectives and Assumptions

2. Market Purview

3. Market Dynamics, Regulations, and Trends Analysis

4. Global Diagnostic Radioisotopes Market - Impact of Coronavirus (COVID-19) Pandemic

5. Global Diagnostic Radioisotopes Market, By Radioisotope, 2023-2030, (US$ Bn)

6. Global Diagnostic Radioisotopes Market, By Application, 2023-2030, (US$ Bn)

7. Global Diagnostic Radioisotopes Market, By Imaging Modality, 2023-2030, (US$ Bn)

8. Global Diagnostic Radioisotopes Market, By Indication, 2023-2030, (US$ Bn)

9. Global Diagnostic Radioisotopes Market, By End User, 2023-2030, (US$ Bn)

10. Global Diagnostic Radioisotopes Market, By Region, 2023-2030, (US$ Bn)

11. Competitive Landscape

12. Section

(ÁÖ)±Û·Î¹úÀÎÆ÷¸ÞÀÌ¼Ç 02-2025-2992 kr-info@giikorea.co.kr
¨Ï Copyright Global Information, Inc. All rights reserved.
PC¹öÀü º¸±â